

PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis

Author name and affiliations:

Zhiwei Xue^{1, 2*}, Mengtao Han^{1, 2*}, Tao Sun^{1, 2*}, Yanzhao Wu^{1, 2}, Wenchen Xing^{1, 2}, Feiyu Mu^{1, 2}, Zhihan Zhang^{1, 2}, Junzhi Liu^{1, 2}, Xiangjun Liang^{1, 2}, Lu Ling^{1, 2}, Jian Wang^{1, 2, 5}, Jiwei Wang^{1, 2}, Xingang Li^{1, 2, 3, 4}, Bin Huang^{1, 2, 3, 4}, Donghai Wang^{1, 2, 3}

1. Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University.

2. Shandong Key Laboratory of Brain Health and Function Remodeling, Jinan 250012, China.

3. Department of Neurosurgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China

4. Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Jinan, China

5. Department of Biomedicine, University of Bergen, Jonas Lies Vei 91, 5009, Bergen, Norway.

* Zhiwei Xue, Mengtao Han and Tao Sun contributed equally to this work

#Corresponding Authors:

Donghai Wang, Ph.D. and M.D. (drwangdonghai@sdu.edu.cn)

Bin Huang, Ph.D. (hb@sdu.edu.cn)

Xingang Li, Ph.D. and M.D. (lixg@sdu.edu.cn)

Word count

6985-word for all words in the text body (Introduction through Discussion) exclusive of references, figure legends.

Funding

This work was supported by the Department of Science & Technology of Shandong Province (ZR2023MH023 and ZR2019ZD33), the Special Foundation for Taishan Scholars (tshw201502056), the Shandong Provincial Laboratory Project (SYS202202) , the Clinical Practical New Technology Development Foundation of Qilu Hospital (grant 2019-7), and the crosswise tasks (contract number: 11691806 and 6010120062).

Conflict of interest statement.

All authors declare no conflicts of interest.

Authorship statement

Z.X., J.W., X.L., B.H. and D.W. designed this study and wrote the paper; Z.X., M.H., T.S., W.X., F.M., Z.Z., J.L., X.L. and L.L. performed the experiments; Z.X., M.H. and Y.W. analyzed the data; T.S. and J.W. collected patient samples. All authors read and approved the final version of the manuscript.

Data Availability Statement

Datasets and other files generated, analyzed, or used during this study are available from the corresponding author upon reasonable request.

Acknowledgments


We thank the Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China for providing HUVEC and MAEC.

We thank the GEO databases and the human protein atlas for providing the public

availability of these large datasets.

We would like to thank BioRender (BioRender.com) for the Schematic drawing.

Graphic Abstract



Abstract

Background

Endothelial-to-mesenchymal transition (EndMT) is a cellular reprogramming mechanism by which endothelial cells acquire a mesenchymal phenotype. Endothelial cell dysfunction is the initiating factor of atherosclerosis (AS). Increasing evidence suggests that EndMT contributes to the occurrence and progression of atherosclerotic lesions and plaque instability. However, the mechanisms leading to EndMT in atherosclerotic plaques' microenvironment are poorly understood.

Methods

Single-cell sequencing data of atherosclerotic plaques in mice fed with high-fat diet for different time periods were analyzed. Using quantitative polymerase chain reaction, western blotting, and immunohistochemistry, we demonstrated that the expression of PIM1 in ox-LDL stimulated endothelial cells and in human and mouse atherosclerotic lesions. *ApoE*^{-/-} C57 mice were injected recombinant adeno-associated virus serotype 9 through tail vein to explore the role of PIM1 in atherosclerosis. Co-immunoprecipitation (Co-IP) was used to verify the substrates of PIM1. Hematoxylin and eosin (H&E) staining, Oil Red O staining, and Masson's trichrome staining were used to assess the size of atherosclerotic plaques, lipid content, and collagen fiber content, respectively.

Results

PIM1 expression in endothelial cells increased with the progression of AS in vivo. Endothelial cell-specific PIM1 knockdown negatively regulated atherosclerosis progression and the EndMT process. Knockdown of PIM1 in endothelial cells in vitro attenuated ox-LDL-induced EndMT. This process was primarily due to the reduction of PIM1, which led to decreased phosphorylation of NDRG1 at Ser330, and subsequently, reduced NDRG1 nuclear translocation. Consequently, the interaction between NDRG1

and PTBP1 was affected, ultimately impacting the mRNA levels of Vimentin, ZEB1, Slug, Snail, N-Cadherin, TAGLN, and α -SMA. The small molecule Max-40279 could inhibit NDRG1 phosphorylation at Ser330 and suppress EndMT.

Conclusion

Our findings revealed the PIM1/P-NDRG1(S330)/PTBP1/EndMT axis as a critical factor promoting AS progression and could generate new strategies to prevent AS.

Key words

Atherosclerosis, Endothelial-to-mesenchymal transition, PIM1, Nuclear translocation, Max-40279

Introduction

Endothelial-to-mesenchymal transition (EndMT) is an intricate cellular process of endothelial cell reprogramming and redifferentiation, characterized by endothelial cell detachment and migration away from the endothelium and, to varying extents, decreasing endothelial properties and acquiring mesenchymal features. EndMT is primarily characterized by cell morphology changes and cell markers alterations. For instance, the expression levels of endothelial cell markers (CD31, VE-Cadherin, ZO-1) decrease, while conversely, the expression levels of mesenchymal cell markers (ZEB1, N-Cadherin, α -SMA, Vimentin, TAGLN, SLUG, SNAIL) increased [1-3]. EndMT has been recognized as a crucial pathophysiological mechanism involved in sustaining chronic vascular inflammation and contributing to the pathogenesis of several diseases, including malignant diseases [4], fibrotic diseases [5], pulmonary arterial hypertension [6], AS [7], diabetes mellitus [8], cavernous malformations [9], and fibrodysplasia ossificans progressive [10]. Numerous triggers, including cytokines, growth factors, oxidative stress, and inflammatory signals, can cause EndMT, and various signaling pathways, most notably the TGF- β pathway, have been linked to EndMT [1, 11].

AS is a progressive vascular disease characterized by the accumulation of lipid, fibrous,

and cellular components within the thickened intima of arteries, forming plaques. Endothelial dysfunction is considered the initial event in the pathogenesis of AS [12-15], and most commonly occurs at branched and curving areas of the vasculature, where the vessels are exposed to disturbed blood flow patterns. Endothelial cells experience oscillatory low-amplitude shear stress (OSS) in these locations, leading to endothelial dysfunction and reprogramming. This includes increased inflammation, permeability, apoptosis, cell proliferation, EndMT, and endothelial cell transformation into immune cells [16], contributing to plaque formation. Once plaques form, the inflammatory, oxidative stress, and high TGF- β environment within the plaques further promote EndMT, creating a vicious cycle [17, 18]. Recent studies have shown that nearly one-quarter of Chinese adults have an increased carotid intima-media thickness (cIMT) or carotid plaque (CP) [19]. For this large population with these conditions, in-depth exploration of the pathogenesis and the search for effective treatment methods are crucial for preventing and managing cardiovascular and cerebrovascular diseases.

Here, we analyzed single-cell sequencing data of atherosclerotic plaques from mice at different stages and found that PIM1 expression in endothelial cells was increased, particularly in advanced plaques, including those from mice on a high-fat diet (HFD) for 26 weeks. PIM1 belongs to the proviral insertion site in Moloney murine leukemia virus, a family of short-lived serine/threonine kinases [20]. Numerous studies have shown that PIM1 can cause pulmonary fibrosis and promote the progression of various tumors by promoting epithelial-to-mesenchymal transition (EMT) [21-25], which is closely related to EndMT [1]. The PIM kinase has also been shown to play an important role in cardiovascular diseases [26]. Based on this body of data, we speculated that expression of PIM1 may govern EndMT. Furthermore, we hypothesized that by modulating EndMT, PIM1 may participate in maintaining endothelial cell homeostasis and advancing AS and plaque instability.

Methods

Data Availability

The authors declare that all supporting data are available in the article and Supplemental Material. The research materials listed in the Methods are included in the Major Resources Table in the Supplemental Material.

FASTQ files of atherosclerotic plaques in mice with atheroprone backgrounds (*Ldlr*^{-/-}) were obtained from the NCBI Gene Expression Omnibus (GEO) database under the accession number GSE155513. The RNA-seq data are available in the GEO database (accession: GSE118446, GSE43292, GSE206927).

Patients and Samples

This study was approved by the ethics committee of Qilu Hospital (KYLL-202111-037-1), informed consent was obtained from all patients prior to the procedure. Patients undergoing CEA for carotid atherosclerotic stenosis or occlusion were enrolled in the study between December 2020 and January 2023. All patients were diagnosed, and other etiologies were excluded by Doppler ultrasound, computed tomography angiography (CTA), magnetic resonance imaging or angiography, and digital subtraction angiography (DSA). The minimum age limit was 18 years. Data on the clinical and demographic characteristics of the participants were gathered from before CEA. The clinical characteristics of the patients are reported in Supplementary Table S1.

Animals

All animal experimental protocols used in this study were approved by the ethics committee of Qilu Hospital, Shandong University (Jinan, China; approval number: DWLL-2023-080). Mice were housed in the Qilu Hospital of Shandong University animal facilities and exposed to light on 12 h cycles in a humidity- and temperature-controlled environment with no pathogenic microorganisms. Endo-*Pim1*^{KD} mice were

established by recombinant adeno-associated virus serotype 9 (AAV9). Eight-week-old male *ApoE*^{-/-} mice were microinjected with either the endothelial cell-specific control shRNA-AAV9 (AAV-ICAM2-empty vector) or *Pim1* shRNA-AAV9 (AAV-ICAM2-sh*Pim1*; 5×10¹¹ vg; Vigene Biosciences, Jinan, China) via the tail vein. The sequence for sh*Pim1* was 5'-CCGAUAGUUUCGUGCUGAU-3'. After 4 weeks, HFD was administered for 16 weeks to develop atherosclerosis.

Cell Culture

Human Vein Endothelial Cells (HUVECs) and Mouse Aortic Endothelial Cells (MAECs) were provided as a gift from the Department of Cardiology, Qilu Hospital of Shandong University, and cultured at 37 °C in 5% CO₂ in Endothelial Cell Medium (Catalog No. 1001, Science Cell) supplemented with 15% fetal bovine serum (FBS) (Catalog No. 0025, Science Cell), 1% Endothelial Cell Growth Supplement (ECGS, Catalog No. 1052, Science Cell), and 1% penicillin/streptomycin solution (P/S, Catalog No. 0503, Science Cell). Mouse Primary Lung Endothelial Cells (MPLECs) were obtained from *ApoE*^{-/-} Endo-*Pim1*^{KD} C57 mice or *ApoE*^{-/-} Endo-Control C57 mice. For each batch of MPLECs, 4 mice were anesthetized by intraperitoneal injection and perfused with 10 mL ice-cold HBSS buffer (14025092, Gibco™). Lungs were removed and rinsed in Dulbecco's Modification of Eagle's Medium (DMEM) (CM10013, Macgene) with 1% anti-biotic/antimycotic (15240062, Gibco™) before being minced using a scalpel. Minced lungs were digested in 20 mL HBSS buffer containing 1% collagenase Type I (17100-017, Gibco™) for 2 hours at 37°C with constant tilting. Cells were then filtered through a 70 µm nylon filter (352350, Falcon) and washed twice before further incubated with 50µL Dynabeads™ CD31 (11155D, Invitrogen™) for 60 minutes at 4 °C on a roller. Bead-bound cells were collected using a magnet, resuspended in Endothelial Cell Medium (Catalog No. 1001, Science Cell), and cultured for at least 7 days to allow adherence and initial expansion [27]. HEK293T cells were cultured at 37 °C in 5% CO₂ in DMEM (CM10013, Macgene) supplemented with 10% FBS and 1% P/S.

EndMT was induced by incubating cells in 50 ng/mL recombinant human TGF- β 2 (HY-P7119, MCE) and 200 mM H₂O₂ (MM0707-500ML, Shanghai Maokang Biotechnology Co., Ltd.) added to complete median days 1 and 3, as described [28].

siRNA Interference, Plasmid Transfection, Lentivirus Infection

Short interfering RNAs (siRNAs) were transiently transfected with Lipofectamine 3000 reagent (L3000150, Thermo Fisher Scientific) following the manufacturer's instructions. For plasmids, transient transfections were performed with Lipofectamine 3000 reagent (L3000150, Thermo Fisher Scientific) following the manufacturer's instructions. The lentivirus used for stable knockdown NDRG1 was purchased from OBiO Technology. Lentiviral infected cells were selected with puromycin and mRNA levels were determined using qRT-PCR. Custom-made siRNA and shRNA-lentivirus sequences are listed in Table S2 and Table S3. The plasmids and the vector used are shown in Table S4.

Quantitative Real-time PCR (qRT-PCR)

Total RNA was extracted using a kit from Yishan Bio (ES-RN001), according to the manufacturer's instructions. cDNA was generated from total RNA using the Hifair III 1st Strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus) (11141ES60, Yeasen). qRT-PCR was performed with Hieff qPCR SYBR Green Master Mix (No Rox) (11201ES08, Yeasen) on the Roche 480II Real-Time PCR Detection System (Roche; Basel, Switzerland). The expression of target mRNA was normalized with β -actin mRNA expression. The primer sequences used are shown in Table S5.

Western Blotting Analysis

Total proteins were extracted with RIPA lysis buffer containing a cocktail of protease inhibitors and phosphatase inhibitors (P0013B, Beyotime). Cytoplasmic and nuclear extracts were prepared according to the instructions of the NE-PER® nuclear and cytoplasmic extraction kit (Pierce) (78833, Thermo Scientific). The concentration of

proteins was determined with the Enhanced BCA Protein Assay Kit (P0009, Beyotime) according to the manufacturer's instructions. Equal amounts of proteins per sample (30 µg) were separated by SDS-PAGE and then electrotransferred onto PVDF membranes (Merck Millipore; Billerica, MA, USA). Membranes were blocked for 10 min in QuickBlock™ Blocking Buffer (P0235, Beyotime), incubated with primary antibodies overnight at 4 °C, and followed by incubation with an HRP-conjugated secondary antibody (ZB-5301, ZB-2305, ZSGB-BIO) for 1 h. ECL (36208ES76, Yeasen) was utilized to detect immunoreactivity. β-actin served as a loading control. The primary antibodies used are listed in Table S6.

Immunofluorescence (IF)

For cellular immunofluorescence staining, 2000 cells per well were seeded overnight into Slide 8 Wells (Ibidi GmbH). Treatments were added to each well on the next day, and after 72 h, each well was fixed with 4% paraformaldehyde in PBS, blocked, and permeabilized for 1 h in 1% BSA. Cells were incubated with primary antibodies overnight at 4 °C at an appropriate dilution, and subsequently for detection, with species-appropriate, fluorescently labeled secondary antibodies for 1 h at room temperature at a dilution of 1:2000. TRITC Phalloidin (40734ES75, Yeasen) was used to visualize F-actin, and DAPI (blue) (C1002, Beyotime) as a nuclear counterstain (30 min. incubation). A Leica TCS SP8 confocal microscope was used to capture the images (Leica Microsystems; Wetzlar, Germany).

For immunofluorescence staining of tissue sections, paraffin sections were incubated at 70 °C for 30 min, dewaxed in xylene and 100% ethanol, and air dried. Sections were washed three times in PBS. Antigen retrieval was then performed with EDTA Antigen Retrieval Solution (P0085, Beyotime) for 30 min at 95 °C, and the sections were allowed to cool at room temperature for 1 h. Frozen sections were directly washed three times in PBS. The sections were incubated with 3% H₂O₂ for 10 min and then blocked for 30 min. (0.5% Triton X-100, 1% BSA, 10% donkey serum). Incubations with primary and secondary antibodies were subsequently performed as described above.

The primary antibodies used are shown in Table S6.

Immunohistochemistry (IHC)

Paraffin sections were processed exactly as described above for IF staining. Sections were incubated with primary antibodies overnight at 4 °C at an appropriate dilution and then performed with Immunohistochemical kit (PV-9000, ZSGB-BIO) following the manufacturer's instructions. The sections were scanned, and images were captured by the WISLEAP Scanning System (WISLEAP Medical Technology Co. LTD). Staining was evaluated independently to determine the histological score according to the proportion of positively stained cells and staining intensity. The primary antibodies used are shown in Table S6.

HE staining and quantification of Lesion Size

The embedded tissues were placed on a slide and were cut using a frozen slicer at the optimal cutting temperature. According to AHA guidelines, we collected cross-sections at a 6 µm distance per section on slides from the origin of the aortic valves to the ascending aorta. The left carotid artery was embedded in paraffin and sectioned, while the right carotid artery was subjected to frozen sections. Both sections were taken at the carotid bifurcation. Sections were stained with hematoxylin for 5 min, rinsed with tap water until the nuclei turned blue, and stained with eosin for 3 min. The sections were dehydrated using different concentrations of ethanol, treated with environmental transparency agent, and sealed with neutral balsam (G8590, Solarbio). Images were captured using the WISLEAP Scanning System (WISLEAP Medical Technology Co. LTD). The plaque areas were determined by the NDP.view software (2.8.24).

Oil Red O Staining

The entire artery was separated and incubated in oil red O (C0158M, Beyotime) solution for 30 min and then washed with staining wash buffer. Images were captured using the Murzider surgical microscope. Frozen sections dried at room temperature

were placed in oil red O for 15 min and then rinsed with staining wash buffer for 2 min. The sections were placed into a hematoxylin staining solution to stain the nuclei for 2 min and then sealed with glycerin gelatin. Images were captured by the WISLEAP Scanning System (WISLEAP Medical Technology Co. LTD). The percentage of Oil Red O positive area were determined by Image-J (1.53C) software.

Masson Staining

Frozen sections dried at room temperature were stained according to the manufacturer's protocol of masson trichrome staining kit (G1340, Solarbio). The sections were dehydrated using different concentrations of ethanol, treated with environmental transparency agent, and sealed with neutral gum. Images were captured by the WISLEAP Scanning System (WISLEAP Medical Technology Co. LTD). The percentage of collagen positive area were determined by Image-J (1.53C) software.

RNA Immunoprecipitation Assay

The Magna RIP Kit (No. 17-701, Millipore) was used for the assay. Briefly, magnetic protein A/G beads pretreated with 5 µg anti-PTBP1 antibody or 5 µg Mouse IgG antibody were added to cell lysates and the samples were incubated at 4 °C under rotation overnight. Then, the beads were washed 6 times and incubated with proteinase K buffer. RNA was extracted from the immunoprecipitates and reversed transcribed. RT-qPCR products were subjected to agarose gel electrophoresis.

Co-immunoprecipitation (Co-IP)

Co-IP was performed with the Pierce™ Classic Magnetic IP/Co-IP Kit (88804, Thermo Fisher Scientific) according to the manufacturer's instructions. The cell lysates were incubated with antibodies (listed in Table S6) or anti-IgG (3420S; Cell Signaling Technology) overnight at 4 °C, and then mixed with Protein A/G magnetic beads (88804, Thermo Fisher Scientific) and incubated for 2 h at room temperature. The

proteins were eluted, separated by SDS–PAGE, and analyzed by western blotting.

Protein purification and surface plasmon resonance (SPR)

SPR was performed with SensiQ (The Pioneer platform, ForteBio; Freemont, CA, USA). First, the SPR chip (Hiscap biosensor, ForteBio) was activated with 1 mM NiCl₂, and 50 µg/mL NDRG1 protein (Ag25424, Proteintech) was immobilized on the chip. PIM1 protein (HY-P701745, MCE), PTBP1 protein (Ag28404, Proteintech), and small molecule Max-40279 (HY-145723, MCE; 500 nM) binding activities were generated with the SPR system, and the binding signal was exhibited by the response (RU) value. The data were normalized to control and analyzed with Qdat (ForteBio). Binding curves were subsequently generated.

Transwell assays

Transwell assays were conducted in 24-well plates. The upper chamber was seeded with HUVECs, MAECs or MPLECs (3×10⁴ cells/300 µL) in FBS-free medium, and the lower chamber was filled with medium supplemented with 15% FBS. Cells that passed through the 8 µm membrane were fixed with 4% paraformaldehyde and stained with crystal violet. Brightfield microscopy images were captured, and the cells were counted.

Scratch wound healing assay

HUVECs, MAECs or MPLECs monolayers treated as indicated in the six well plate and were scratched with a 200-µL pipette tip. Cells were washed once, and 2% serum medium was added to prevent confounding effects of FBS–induced cell proliferation. Images were taken at 0- to 12 h time points, and cell migration was determined by measuring changes in scratch area over time using Image-J (1.53C) software.

Mass Spectrometry (MS)

Co-immunoprecipitated proteins were subjected to analysis by MS. In brief, the co-immunoprecipitated protein samples were separated by SDS-PAGE gel electrophoresis and stained with Coomassie Brilliant Blue to visualize the protein

bands. The gel bands were then subjected to in-gel digestion, and the protein composition of the samples was determined using MS. The MS was conducted by Novogene Co. Ltd.

Protein-Protein Docking

Protein-protein docking is a computational method used to predict the near-native structure of a protein complex based on the known three-dimensional structures of two individual proteins. Docking involves both sampling and scoring processes. In this study, protein docking was performed using the HDock server. HDock combines physical and bioinformatics-based approaches to develop efficient molecular docking algorithms and accurate scoring functions for biomolecular interactions. HDock samples all possible binding modes between two separate proteins. The scoring function then ranks the sampled binding modes based on their likelihood. Using the HawkDock server, the binding free energy of the two proteins was calculated using the MM/GBSA method. The binding process of the two proteins was visualized in surface representation. The binding interface of the protein-protein complex was comprehensively described and systematically analyzed using the PLIP interaction analysis platform. Additionally, interaction details were further supplemented using PyMOL.

Statistical analyses

Statistical analyses were performed using GraphPad Prism (version 8.3; GraphPad Software, CA). The observed results are presented as mean \pm SD. For independent samples, differences between two groups with equal variance were analyzed using a two-tailed Student's t-test. One-way ANOVA was used to determine differences among multiple groups with equal variance. All statistical data are derived from biological replicates. $P < 0.05$ was considered statistically significant.

Results

PIM1 is Significantly Elevated in Human Unstable Carotid Atherosclerosis Plaques and Mouse Advanced Atherosclerosis Plaques

To identify genes involved in the AS progression through the EndMT process, we reanalyzed previous single-cell sequencing (scRNA-seq) data (GSE155513) [29]. We obtained 28816 cells from different plaques in mice fed with a HFD for 0, 8, 16, or 26 weeks after batch correction. Based on key cell markers, we defined 11 cell types including smooth muscle cells (SMC), SMC-derived intermediate stem cells (ICS-SEM), fibrochondrocytes (FC), macrophages 1, 2, 3, minor SMC, fibroblasts1, 2, T cell, and endothelial cell (EC) (Figure 1A-B). Subsequently compared the gene expression levels of endothelial cells from plaques at different stages (Figure 1C). To further identify genes involved in the EndMT process, we analyzed the transcriptome sequencing (RNA-seq) data (GSE118446) [29] of HUVECs-induced EndMT (Figure 1D) and intersected the results with the differentially expressed genes (DEGs) obtained from the scRNA-seq data (Figure 1E). The Venn diagram showed 13 overlapping genes, including FN1, CALD1, COL5A2, COL8A1, EDN1, FBLN5, SDC4, LGMN, LUM, LGALS3, TUBB3, DCN, PIM1. We selected PIM1 for further analysis because, as a signaling factor, it integrates multiple signaling pathways and regulates the expression of various downstream genes. This versatility makes PIM1's role in disease progression more complex and significant compared to other genes with relatively singular functions. Next, we analyzed PIM1 expression levels in four groups of endothelial cells and found that its expression level and proportion increased with the progression of plaques (Figure 1F). We also examined the PIM1 expression of other cells in various stages of atherosclerotic plaques. The results indicate that in smooth muscle cells (SMCs), the number of PIM1-positive cells initially decreased and then increased, while the proportion of PIM1-positive cells consistently rose (Figure S1A). In T cells, the number of PIM1-positive cells continuously increased, but the positive proportion initially decreased before rising again (Figure S1B). In ICS (SEM),

the number of PIM1-positive cells showed a decline followed by an increase, with no significant change in proportion (Figure S1C). In fibroblasts, the number of PIM1-positive cells decreased, then increased, and subsequently decreased again, while their proportion steadily rose (Figure S1D). In macrophages, the number of PIM1-positive cells continuously increased, with a sharp rise in the positive proportion during week 8 of plaque formation, followed by a slight decline, but ultimately remained elevated (Figure S1E). To validate the conclusions of the analysis above, we extracted proteins from the thoracic and abdominal aortas of *ApoE*^{-/-} mice subjected to the normal diet or HFD for 16 weeks and assessed PIM1 protein expression. The results indicated that HFD promoted the expression of PIM1 in both the thoracic and abdominal aortas (Figure 1G, Figure S2A). Moreover, immunohistochemical and immunofluorescence staining of carotid artery sections was performed to detect PIM1 in endothelial cells. As expected, the PIM1 protein levels were significantly upregulated in endothelial cells in the carotid atherosclerotic plaques (Figure 1H, Figure S2B). RNA-seq of human carotid atherosclerotic plaques (GSE43292) yielded similar findings, showing higher levels of PIM1 mRNA expression in these plaques (Figure 1I). More importantly, we randomly selected 10 stable and 10 unstable plaques from our own repository of carotid atherosclerotic plaque specimens, obtained through carotid endarterectomy, and performed immunohistochemistry and immunofluorescence staining to detect PIM1 expression levels. The results revealed that PIM1 expression was significantly higher in unstable plaques compared to stable plaques, predominantly localized in the endothelial cells of neo-vessels within the plaques (Figure 1J, Figure S2C). These endothelial cells exhibited distinct mesenchymal characteristics.

These findings indicated that PIM1 expression is markedly elevated in atherosclerotic plaques and is closely associated with EndMT and plaque neovascularization, potentially contributing to plaque instability.

PIM1 is Upregulated in Endothelial cells under the Conditions of ox-LDL Stimulation.

Since ox-LDL plays a crucial role in AS, we stimulated HUVECs, (MAECs), and MPLECs with 100 µg/mL ox-LDL. All three cell lines exhibited decreased expression of endothelial markers such as CD31 and increased expression of mesenchymal markers, including ZEB1, Snail, Slug, and α -SMA, under ox-LDL stimulation (Figure 2A-C). This indicates that ox-LDL significantly promotes EndMT. RNA-seq of HUVEC treated with ox-LDL (GSE206927) showed that PIM1 was upregulated compared to the control group (Figure S3A). Similarly, using a previously published method [27, 28] of EndMT induction, HUVEC and MAEC showed results similar to those under ox-LDL stimulation (Figure S3B-C). More importantly, stimulation with either ox-LDL or TGF- β and H₂O₂ significantly increased PIM1 expression in endothelial cells (Figure 2D-E). This conclusion was further corroborated by Western blot analysis (Figure 2F-G, Figure S3D-I). Immunofluorescence and cytoskeletal staining demonstrated that EndMT markedly altered cell morphology and significantly increased PIM1 expression (Figure 2H-I). Furthermore, two distinct isoforms of PIM1 were localized in the cytoplasm and nucleus (Figure 2H-I), with PIM1-L primarily in the cytoplasm and PIM1-S mainly in the nucleus [30].

In conclusion, these data suggested that PIM1 may be involved in endothelial cell function and EndMT.

PIM1 Silence Attenuates the Process of EndMT

To investigate the regulatory role of PIM1 in EndMT, we silenced PIM1 expression using siRNA in HUVECS and MAECS and then assessed the expression of endothelial and mesenchymal markers under EndMT induction. Both qRT-PCR and Western blot results indicated that under EndMT induction, knocking down PIM1 could suppress the expression of mesenchymal markers such as α -SMA, Slug, and Snail, while restoring the expression of endothelial markers including CD31 and VE-Cadherin (Figure 3A-C;

Figure S4A-D). After knocking down PIM1 in HUVECs, we stimulated the cells with ox-LDL for 48 hours and then extracted proteins. Western blot experiments demonstrated that PIM1 knockdown mitigated ox-LDL-induced EndMT (Figure 3D). PIM447, an inhibitor of PIM1, has the same effect (Figure S5A-D). It has been reported that endothelial cells undergo significant morphological changes and exhibit enhanced migratory ability [1]. Therefore, under EndMT-inducing conditions, we assessed the migratory ability of endothelial cells after silencing PIM1 using Wound closure and Transwell assays. The results showed that inhibiting PIM1 expression significantly suppressed the enhanced migratory ability of endothelial cells induced by EndMT (Figure 3G, Figure S6A-C). For atherosclerotic plaques, this would significantly increase the barrier function of vascular endothelium, reducing plaque instability caused by increased endothelial cell migratory ability.

Endothelial Cell-Specific PIM1 Knockdown Reduces EndMT and Attenuates Atherosclerotic Plaque progress

Since PIM1 expression was elevated in the endothelial cells of atherosclerotic plaques, we wanted to determine whether PIM1 knockdown inhibited the process of EndMT and attenuated atherosclerotic plaques progress. Firstly, we conducted a small-scale pilot experiment. *ApoE^{-/-}* mice were fed an HFD to establish an atherosclerotic plaque mouse model. After 8 weeks on the HFD, we initiated PIM447 or PBS intervention (n = 5, every group), which continued for another 8 weeks while maintaining the high-fat diet. The administration of PIM447 and PBS was performed via oral gavage at a dosage of 100 mg/kg, five times a week. Subsequently, we collected the mice's vascular tissues for analysis (Figure 4A). The results showed that PIM447 can prevent the progression of atherosclerotic plaques (Figure 4B-E), reduce the infiltration of macrophages (Figure 4F-G) and endothelial cell inflammation (Figure S7A-B) in plaques. Furthermore, PIM447 can inhibit the process of EndMT (Figure S8A-F).

Endothelial cell-specific *Pim1* knockdown was established by recombinant adeno associated virus serotype 9 (rAAV9) (Figure S9A). After 4 weeks, the PIM1 protein

levels in the MPLECs from endothelial cell-specific *Pim1*^{KD}-rAAV9 (Endo-*Pim1*^{KD}) and endothelial cell-specific *Control*-rAAV9 (*Control*) *ApoE*^{-/-} mice (Figure S9B) were detected by Western-blot. The results confirmed the absence of PIM1 expression in endothelial cell from endothelial cell-specific *Pim1*^{KD}-rAAV9 *ApoE*^{-/-} mice (Figure S9C). More important, under the EndMT induction, the expression of mesenchymal markers such as α -SMA, Slug, and Snail were downregulated on the MPLEC from Endo-*Pim1*^{KD} mice, while the expression of endothelial markers including CD31 and VE-Cadherin were restored (Figure S9C). Next, endothelial cell-specific *Pim1*^{KD}-rAAV9 *ApoE*^{-/-} mice and *Control*-rAAV9 *ApoE*^{-/-} mice were fed an HFD for 16 weeks to develop AS (Figure S9A). *ApoE*^{-/-}-Endo-*Pim1*^{KD} mice had fewer atherosclerotic plaques in the aortic arch, carotid artery, and aortic root than the *ApoE*^{-/-}-*Control* mice (Figure 5A-D). In addition, the oil red O staining revealed more minor lipid lesions in the aortic root and carotid artery in *ApoE*^{-/-}-Endo-*Pim1*^{KD} mice than in *ApoE*^{-/-}-*Control* mice (Figure 5B-D). Also, Masson staining showed *Pim1* knockdown increased the content of collagen and the ratio of fibrous cap in the aortic root and carotid artery atherosclerosis plaques (Figure 5C-D; Figure S10A-B). PIM1 knockdown also reduced the infiltration of macrophages (Figure S10C) and endothelial cell inflammation (Figure S10D-E) in plaques. We next performed immunohistochemical to assess the expression of PIM1 and EndMT markers in the endothelial cell of aortic root and carotid artery plaques. Compared with plaques from *ApoE*^{-/-}-*Control* mice, plaques from *ApoE*^{-/-}-Endo-*Pim1*^{KD} mice showed lower protein levels of PIM1, Slug, Snail, α -SMA, and TAGLN but higher protein levels of VE-Cadherin (Figure 5E-H; Figure S11A-D).

These findings indicated that in the setting of atherosclerosis, the absence of PIM1 in endothelial cells is associated with reduced EndMT, reduced atherosclerotic burden, and a more favorable plaque phenotype.

PIM1 Promotes the EndMT of Endothelial cell through phosphorylation of NDRG1 at Ser-330

We next investigated how PIM1 regulated EndMT. Previously, it was reported that

PIM1 is a proto-oncogene, encoding a serine/threonine protein kinase, involved in various biological processes by phosphorylating multiple target substrates [20, 31, 32]. Therefore, we first screened its target proteins by immunopurification and MS in vitro. To this end, myc-PIM1 was ectopically expressed in 293T cells. The whole-cell extracts were prepared and subjected to affinity purification using Myc-Tag antibody and IgG antibody. The eluted protein complex was then resolved on sodium dodecyl sulfate–polyacrylamide gel electrophoresis, Coomassie Blue stained and subjected to LC–MS/MS analysis (Figure 6A). The identified proteins were listed in Supplementary Table S7. Previous studies have explored the phosphorylation substrates of PIM1 [33]. Protein kinases promote phosphorylation reactions by binding to the substrates, enhancing the specificity and facilitating conformational changes at the catalytic site, thereby increasing the efficiency of phosphate transfer. Such binding typically depends on the specific amino acid sequence of the substrate and the binding pocket of the kinase. The affinity and binding kinetics between kinases and substrates have been shown to be crucial for their function [34–36]. Next, by intersecting our mass spectrometry results with phosphorylation substrates, we identified NDRG1 (Figure 6B). We hypothesized that PIM1 promotes EndMT by facilitating the phosphorylation of NDRG1 at the Ser-330 site. Our analysis showed that during EndMT, the phosphorylation level of NDRG1 at Ser-330 was significantly increased (Figure 6C, Figure S12A). However, upon PIM1 knockdown, the phosphorylation of NDRG1 at Ser-330 was inhibited (Figure 6D, Figure S12B), indicating that PIM1 could bind to NDRG1 and promote phosphorylation of the Ser-330 site of NDRG1. We conducted molecular simulations and protein docking to investigate further the binding domains of PIM1 and NDRG1. The binding free energy calculated by the MM/GBSA method using the HawkDock server was -34.31 (kcal/mol). There are 15 hydrogen bonds (within 4.1 Å) and two salt bridges formed between the proteins. As shown in Figure 6E (a), a hydrogen bond (blue solid line) was formed between PIM1's ASP-195 and NDRG1's LYS-280, and hydrogen bonds were formed between PIM1's ARG-217 and HIS-219 with NDRG1's THR-279, with a salt bridge

(yellow dashed line) also formed between PIM1's ARG-217 and NDRG1's ASP-277. In Figure 6E (b), a hydrogen bond was formed between NDRG1's ALA-385 and PIM1's ARG-214, another between PIM1's ARG-221 and NDRG1's GLY-311, along with a hydrogen bond and salt bridge between NDRG1's LYS-388 and PIM1's GLU-211. In Figure 6E (c), a hydrogen bond is formed between NDRG1's GLY-386 and PIM1's ARG-214, another between PIM1's TYR-215 and NDRG1's LYS-388, and yet another between NDRG1's THR-282 and PIM1's ARG-274. Finally, in Figure 6E (d), two hydrogen bonds were formed between PIM1's ARG-268 and NDRG1's SER-330, and hydrogen bonds were formed between NDRG1's GLY-331 and PIM1's PHE-255 and GLN-264, as well as between NDRG1's SER-332 and PIM1's VAL-259 and ARG-258. Figure 6E also shows the presence of multiple hydrophobic interactions. Furthermore, as displayed in Figure S12C, in HUVECs, immunoprecipitation of PIM1 and NDRG1 resulted in co-immunoprecipitation of NDRG1 and PIM1, respectively, but the anti-IgG antibody did not immunoprecipitate PIM1 or NDRG1. We therefore performed in vitro SPR assays, which demonstrated considerable affinities and direct binding between PIM1 and NDRG1 (Figure S12D). Based on the protein docking results, we designed two truncated mutants of NDRG1 spanning amino acids 180-294 and 326-394 and overexpressed them with the wild-type NDRG1-His-Tag, in 293T cells. Using an anti-His-Tag antibody for immunoprecipitation, we found that both truncated mutants could bind to PIM1 (Figure 6F). Given that PIM1 has only one structural domain, we mutated the amino acids that form hydrogen bonds with NDRG1 according to the docking results (Figure 6G). Subsequent Co-IP experiments confirmed that the binding affinity between PIM1 and NDRG1 decreased after mutation (Figure 6H). This further validated our molecular docking results. Confocal immunofluorescent staining demonstrated strong localization of PIM1 and NDRG1 in HUVECs and MAECs (Figure 6I, Figure S12E). Unexpectedly, under EndMT-inducing conditions, NDRG1 appeared to have increased expression in the nucleus (Figure 6I, Figure S12E). To further validate this phenomenon, we performed nuclear-cytoplasmic fractionation followed by Western blot analysis. The results indicated that EndMT induction promoted the

nuclear translocation of NDRG1 in endothelial cells (Figure 6J, Figure S12F), while PIM1 knockdown inhibited this process (Figure 6K-L, Figure S12G). Previous studies have also suggested that phosphorylation of NDRG1 at the Ser-330 site may facilitate its nuclear translocation [37], which is consistent with our findings.

NDRG1 is Required for PIM1-Induced EndMT

We have demonstrated that PIM1 promoted the NDRG1 phosphorylation at the Ser-330 site, but the regulatory role of NDRG1 in EndMT remained unknown. Therefore, we constructed NDRG1-knockdown in HUVECs using lentivirus and assessed EndMT expression levels under EndMT-inducing conditions. The results showed that NDRG1 knockdown inhibited the expression of mesenchymal markers such as ZEB1, α -SMA, Slug, Snail, and TAGLN, while restoring the expression of endothelial markers like CD31 and VE-Cadherin (Figure 7A-B, Figure S13A). NDRG1 knockdown also reduced the migratory ability of HUVECs (Figure 7C). Furthermore, after knocking down PIM1, we constructed a phospho-mimetic NDRG1 mutant plasmid, NDRG1(S330D), for rescue experiments. The results showed that overexpressing NDRG1(S330D) completely abolished the inhibitory effect of PIM1 knockdown or PIM447 on EndMT and further promoted EndMT (Figure 7D-E, Figure S13B-C).

Small-molecule drugs have significant advantages in inhibiting protein-protein interactions and blocking phosphorylation and other protein modification sites. Therefore, we downloaded 11,586 small-molecule drugs from DrugBank (<https://go.drugbank.com/>) and performed high-throughput docking with the Ser-330 site of NDRG1 using AutoDock Vina software. We selected the top five small molecule drugs with the lowest binding energies as potential inhibitors for visualization analysis and validation (Table S8, Figure 7F). Furthermore, we performed in vitro SPR assays, which demonstrating considerable affinities and direct binding between Max-40279 and NDRG1 (Figure S14A). Finally, we demonstrated that Max-40279 significantly inhibits the phosphorylation of NDRG1 at Ser-330 (Figure 7G, Figure S14B-D). Additionally, the presence of Max-40279 also reduced the total protein level of NDRG1.

We speculate that Max-40279 may promote the degradation of NDRG1 upon binding, though we did not investigate this further. Western blot results showed that under EndMT-inducing conditions, the addition of Max-40279 in HUVECs, MAECs, and MPLECs significantly inhibited the expression of mesenchymal markers such as ZEB1, α -SMA, Slug, Snail, and TAGLN (Figure 7G, Figure S14B-D), as well as the migratory capacity of endothelial cells (Figure 7H, Figure S14E, F).

Thus, we have shown that NDRG1 mediates PIM1-induced EndMT, while Max-40279 can impede EndMT by inhibiting NDRG1 phosphorylation at Ser-330.

NDRG1 and PTBP1 collaborate to promote EndMT

Although phosphorylation of the Ser-330 site of NDRG1 has been shown to facilitate its nuclear translocation, the underlying mechanisms promoting EndMT within the nucleus remain unclear. To elucidate this, we overexpressed NDRG1 (S330D) in HUVECs and performed proteomic analysis of nuclear proteins (Figure 8A-B). The identified proteins their enrichment levels and *p*-values were listed in supplementary Table 9. Our findings revealed that NDRG1 interacted with PTBP1 in the nucleus. Several studies have demonstrated that PTBP1 could promote EMT [38-40], and advance AS progression by promoting endothelial cell inflammation [41]. These findings are consistent with our study. Immunoprecipitation of NDRG1 in HUVECs led to co-immunoprecipitation of PTBP1. Similarly, immunoprecipitation of PTBP1 resulted in co-immunoprecipitation of NDRG1, whereas the anti-IgG antibody did not immunoprecipitate PIM1 or NDRG1 (Figure 8C). Next, molecular simulations and protein docking were performed to investigate further the binding domains of NDRG1 and PTBP1 (Figure 8D). Using the HawkDock server, the calculated binding free energy was -66.29 kcal/mol, with 14 hydrogen bonds (within 4.1 Å) and one salt bridge forming between the proteins. As shown in Figure 8E (a), a hydrogen bond is formed between ASN-264 of PTBP1 and GLN-185 of NDRG1 (blue solid line), between LYS-266 of PTBP1 and ASP-189 of NDRG1, and between HIS-209 of NDRG1 and TYR-267 of PTBP1. In Figure 8E (b), a hydrogen bond is formed between GLY-222 of

NDRG1 and THR-217 of PTBP1, between LYS-271 of PTBP1 and VAL-216 of NDRG1, and between ASN-217 of NDRG1 and SER-285 of PTBP1. Figure 8E (c) shows hydrogen bonds forming between HIS-69 of NDRG1 and LYS-410 of PTBP1, and between LYS-70 of NDRG1 and SER-288 of PTBP1. In Figure 8E (d), a hydrogen bond is formed between LEU-408 of PTBP1 and GLY-102 of NDRG1. As shown in Figure 8E (e), a hydrogen bond between GLN-33 of NDRG1 and ASN-372 of PTBP1, with ASN-372 forming an additional hydrogen bond with ASP-31 of NDRG1, and a salt bridge between GLU-29 of NDRG1 and ARG-418 of PTBP1. Figure 8E (f) shows a hydrogen bond forms between ARG-405 of PTBP1 and SER-43 of NDRG1, while a salt bridge forms between ARG-405 of PTBP1 and GLU-38 of NDRG1 (yellow dashed line). Additionally, ASP-36 of NDRG1 forms hydrogen bonds with both SER-342 and ASN-376 of PTBP1. Furthermore, multiple hydrophobic interactions (grey dashed lines) were observed (Figure 8D-E). We also performed in vitro SPR assays, demonstrating considerable affinities and direct binding between NDRG1 and PTBP1 (Figure S15A). We then overexpressed the wild-type NDRG1-His-Tag, the mutant NDRG1 (180-294aa)-His-Tag, and the mutant NDRG1 (326-394aa)-His-Tag that were previously constructed in 293T cells. Using an anti-His-Tag antibody for immunoprecipitation, we found that both truncated mutants could bind to PTBP1 (Figure 8F). Additionally, confocal immunofluorescent staining demonstrated a predominantly localization of NDRG1 and PTBP1 in HUVECs and MAECs, particularly under conditions that induce EndMT, NDRG1 and PTBP1 exhibit a stronger colocalization predominantly within the nucleus. (Figure 8G, Figure S15B). It is well known that PTBP1 is an RNA-binding protein. We subsequently performed an RNA Binding Protein Immunoprecipitation (RIP) assay to detect the binding of PTBP1 to the mRNAs of Vimentin, Slug, Snail, α -SMA, N-Cadherin, TAGLN, and ZEB1. The results indicated that PTBP1 can bind to all these mRNAs (Figure 8H, Figure S16A). Additionally, we used protein-RNA docking methods to further confirm these interactions (Figure S16B-H). These findings indicate that the process by which phosphorylated NDRG1 promoted EndMT was dependent on the RNA-binding function of PTBP1. Further investigation revealed that knocking

down NDRG1 results in a decrease in PTBP1 levels within the cell, particularly in the nucleus, without affecting PTBP1 mRNA levels. (Figure 8I-K, Figure S16I) This suggests that NDRG1 may enhance the stability of PTBP1, protecting it from degradation.

Together, these data strongly supported the notion that PIM1 expression was significantly upregulated under ox-LDL stimulation. PIM1 promoted the phosphorylation of NDRG1 at the Ser330 site, facilitating NDRG1's translocation into the nucleus. Once inside the nucleus, NDRG1, through the RNA-binding function of PTBP1, promotes EndMT, leading to decreased stability of atherosclerotic plaques and accelerated progression of atherosclerosis. Therefore, targeting the PIM1/NDRG1/PTBP1 axis may represent a novel strategy for treating AS.

Discussion

AS is the most common cause of cardiovascular and cerebrovascular diseases. The rupture of carotid atherosclerotic plaques can lead to stroke, severely impacting the quality of life. It is a chronic process involving cellular phenotypic transformation, metabolic alterations, and inflammatory events [42, 43]. EndMT is believed to play a crucial role in the initiation and progression of AS [28, 44]. EndMT is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g. myofibroblast, smooth muscle cell)[45]. There are no universally agreed-upon criteria for defining EndMT at the molecular level. However, it is primarily characterized by the downregulation of endothelial markers such as CD31 and VE-Cadherin, and the upregulation of mesenchymal markers such as Vimentin, ZEB1, N-Cadherin, Slug, Snail, α -SMA, and TAGLN. Many characteristics of atherosclerotic plaques, including hypoxia, disturbed flow, oxidative stress, and the TGF- β signaling pathway can activate EndMT [28]. As the innermost layer of blood vessels, endothelial cells play crucial roles in maintaining selective permeability barriers, coordinating leukocyte transport, preventing thrombus formation, and regulating vascular tone. During EndMT, endothelial cells undergo functional

impairment, lose their polarity, and reshape endothelial cell-cell connections, resulting in the migration of monocytes and macrophages into the vessel wall, increased retention of low-density lipoprotein, and the initiation of atherosclerotic plaque formation. The vicious cycle between EndMT and AS can be explained by the fact that endothelial cells experiencing EndMT establish a positive feedback loop, which further exacerbates endothelial dysfunction and leads to the onset and progression of atherosclerosis. Indeed, besides atherosclerosis, EndMT plays a significant role in various other cardiovascular and cerebrovascular-related diseases, including valvular disease, fibroelastosis, vein graft remodeling, cardiac fibrosis, and pulmonary hypertension [46].

Our results indicated that prolonged exposure of endothelial cells to a high-lipid environment, induced EndMT. This process results in the loss of some endothelial cell characteristics, enhanced migratory ability, and weakened barrier function, thereby facilitating the infiltration of macrophages and other cells into the subendothelial space [47]. Our data also showed that stimulation by ox-LDL significantly upregulates the expression of PIM1 in endothelial cells. PIM1, a serine/threonine kinase, increases the phosphorylation of NDRG1 at the Ser330 site. Phosphorylated NDRG1 undergoes subcellular localization changes, altering its mode of action within the cell. Specifically, phosphorylated NDRG1 translocates from the cytoplasm to the nucleus, where it interacts with PTBP1. This interaction inhibits the degradation of PTBP1, allowing PTBP1 to bind to the RNAs of Vimentin, TAGLN, α -SMA, Slug, Snail, and ZEB1, thereby promoting EndMT. However, the mechanisms underlying EndMT require further investigation.

Our study also revealed increased PIM1 expression with the progression of AS, with higher expression in unstable plaques. Single-cell sequencing data that the increase in PIM1 occurs mainly in endothelial cells, macrophages and SMCs. Immunofluorescence staining confirmed the upregulation of PIM1 mainly occurs in the endothelium of neo-vessels within unstable plaques and macrophages surrounding

these neo-vessels, while it is scarce in SMCs. This difference may be attributed to the fact that single-cell sequencing is based on transcriptome data, whereas immunofluorescence staining is based on protein expression. These data indicated that the expression and localization of PIM1 not only differ at the transcriptional level but also suggest that post-translational modifications likely play a crucial role in PIM1 expression. In addition to our study, others have also demonstrated that PIM1 plays an important role in endothelial regulation. For example, PIM1 can directly phosphorylates and stabilizes HIF-1 α to drive angiogenesis in solid tumors[48]. Furthermore, PIM1 promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser-633 [32]. Together with our findings, these studies reinforce the fact that PIM1 is of critical importance for governing endothelial function and pathobiology. As for why PIM1 is also highly expressed in macrophages surrounding neovessels, our study did not delve into this aspect, which is a limitation of our research. Based on existing studies, we speculate that PIM1 may promote the inflammatory response of macrophages [49-51]. Inflammatory macrophages tend to accumulate around neovessels, leading to the instability of atherosclerotic plaques and adverse outcomes. In light of this finding, we have begun to investigate in depth the role and mechanism of PIM1 in macrophages.

Although our study demonstrates that PIM1 promotes the phosphorylation of NDRG1, leading to its nuclear translocation and the subsequent progression of EndMT and atherosclerosis, it is important to note that other mechanisms by which NDRG1 promotes atherosclerosis progression still exist. For example, Zhang et.al identified NDRG1 as a critical mediator implicated in regulating endothelial inflammation and vascular remodeling through regulating Nur77/NF- κ B and AP1 transcriptional pathways [52]. In addition to promoting AS, NDRG1 also contributes to the progression of other diseases through the mechanisms of EndMT or epithelial-to-mesenchymal transition (EMT). NDRG1 facilitates the progression of bladder cancer [53], liver cancer [54], ovarian cancer [55], prostate cancer [56], and esophageal squamous cell carcinoma [57] via EMT. We identified numerous small-molecule drugs that can bind

to the Ser330 site on NDRG1 through molecular docking. These molecules could potentially act as inhibitors or activators. Based on their binding free energies, we selected the top 5 small molecule drugs for validation. We purchased Max-40279, Naftazone, and Stenoparib from MCE to validate their effects on the phosphorylation level of NDRG1. Naftazone and Stenoparib did not affect NDRG1 phosphorylation at the Ser330 site, while Max-40279 significantly reduced the phosphorylation level of NDRG1. Surprisingly, Max-40279 also significantly reduced the protein level of NDRG1. This indicates that regardless of the mechanism by which NDRG1 promotes the progression of atherosclerosis, Max-40279 could be a potential therapeutic option for atherosclerosis by inhibiting NDRG1. Max-40279 is a dual inhibitor of FLT3 kinase and FGFR kinase. It has the potential for researching acute myeloid leukemia (AML) (Patent WO2021180032A1). Due to the lack of reference for dosages in mice, this study did not verify the therapeutic effect of Max-40279 in an AS mouse model, which is a limitation of this study. We plan to explore the dosage and efficacy through the use of nanovesicles targeted to plaques in future studies, aiming to provide new strategies for the treatment of AS.

In conclusion, our study demonstrates a unique role for PIM1 in vascular pathology by promoting EndMT, which is associated with increased AS and an unstable plaque phenotype. Furthermore, we have shown that PIM1 inhibition effectively attenuates EndMT in vitro and in vivo. The mechanism by which PIM1 promotes AS is mainly through the PIM1/NDRG1(Ser330)/PTBP1/EndMT pathway. Targeting of PIM1 or NDRG1 may be beneficial for plaque stabilization or slowing the progression of atherosclerotic disease.

References

1. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. *Circulation*. 2012; 125: 1795-808.
2. Gole S, Tkachenko S, Masannat T, Baylis RA, Cherepanova OA. Endothelial-to-Mesenchymal Transition in Atherosclerosis: Friend or Foe? *Cells*. 2022; 11 (19):2946.
3. Li A, Peng W, Xia X, Li R, Wang Y, Wei D. Endothelial-to-Mesenchymal Transition: A Potential Mechanism for Atherosclerosis Plaque Progression and Destabilization. *DNA Cell Biol*. 2017; 36: 883-91.
4. Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'--more than meets the eye. *Trends Mol Med*. 2013; 19: 447-53.
5. Mina SG, Huang P, Murray BT, Mahler GJ. The role of shear stress and altered tissue properties on endothelial to mesenchymal transformation and tumor-endothelial cell interaction. *Biomicrofluidics*. 2017; 11: 044-104.
6. Tudor RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol*. 1994; 144: 275-85.
7. Zhu X, Wang Y, Soaita I, Lee HW, Bae H, Boutagy N, et al. Acetate controls endothelial-to-mesenchymal transition. *Cell Metab*. 2023; 35: 1163-78.e10.
8. Cao Y, Feng B, Chen S, Chu Y, Chakrabarti S. Mechanisms of endothelial to mesenchymal transition in the retina in diabetes. *Invest Ophthalmol Vis Sci*. 2014; 55: 7321-31.
9. Bravi L, Malinverno M, Pisati F, Rudini N, Cuttano R, Pallini R, et al. Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. *Stroke*. 2016; 47: 886-90.
10. Medici D, Olsen BR. The role of endothelial-mesenchymal transition in heterotopic ossification. *J Bone Miner Res*. 2012; 27: 1619-22.
11. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. *Nat Commun*. 2017; 8: 143-61.
12. Lusis AJ. Atherosclerosis. *Nature*. 2000; 407: 233-41.
13. Caro CG, Fitz-Gerald JM, Schroter RC. Arterial wall shear and distribution of early atheroma in man. *Nature*. 1969; 223: 1159-60.
14. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. *Jama*. 1999; 282: 2035-42.
15. Baeyens N, Bandyopadhyay C, Coon BG, Yun S, Schwartz MA. Endothelial fluid

- shear stress sensing in vascular health and disease. *J Clin Invest*. 2016; 126: 821-8.
16. Li YS, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. *J Biomech*. 2005; 38: 1949-71.
 17. Andueza A, Kumar S, Kim J, Kang DW, Mumme HL, Perez JI, et al. Endothelial Reprogramming by Disturbed Flow Revealed by Single-Cell RNA and Chromatin Accessibility Study. *Cell Rep*. 2020; 33: 108491.
 18. Tamargo IA, Baek KI, Kim Y, Park C, Jo H. Flow-induced reprogramming of endothelial cells in atherosclerosis. *Nat Rev Cardiol*. 2023; 20: 738-53.
 19. Fu J, Deng Y, Ma Y, Man S, Yang X, Yu C, et al. National and Provincial-Level Prevalence and Risk Factors of Carotid Atherosclerosis in Chinese Adults. *JAMA Netw Open*. 2024; 7: e2351225.
 20. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. *Med Res Rev*. 2014; 34: 136-59.
 21. Rang Z, Yang G, Wang YW, Cui F. miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. *Biochem Biophys Res Commun*. 2016; 474: 315-20.
 22. Zhang X, Zou Y, Liu Y, Cao Y, Zhu J, Zhang J, et al. Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells. *Mol Immunol*. 2020; 125: 15-22.
 23. Gao X, Liu X, Lu Y, Wang Y, Cao W, Liu X, et al. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. *Breast Cancer*. 2019; 26: 663-71.
 24. Zhao B, Liu L, Mao J, Zhang Z, Wang Q, Li Q. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis. *Cell Death Dis*. 2018; 9: 307.
 25. Chua HH, Chang MH, Chen YH, Tsuei DJ, Jeng YM, Lee PH, et al. PIM1-Induced Cytoplasmic Expression of RBMY Mediates Hepatocellular Carcinoma Metastasis. *Cell Mol Gastroenterol Hepatol*. 2023; 15: 121-52.
 26. Nock S, Karim E, Unsworth AJ. Pim Kinases: Important Regulators of Cardiovascular Disease. *Int J Mol Sci*. 2023; 24(14):11582 .
 27. Lecce L, Xu Y, V'Gangula B, Chandel N, Pothula V, Caudrillier A, et al. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. *J Clin Invest*. 2021; 131(15):e131178.
 28. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. *Nat Commun*. 2016; 7: 11853.

29. Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. *Circulation*. 2020; 142: 2060-75.
30. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. *Embo j*. 1991; 10: 655-64.
31. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. *J Vet Sci*. 2001; 2: 167-79.
32. Chen M, Yi B, Zhu N, Wei X, Zhang GX, Huang S, et al. Pim1 kinase promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser-633. *Cardiovasc Res*. 2016; 109: 141-50.
33. Ledet RJ, Ruff SE, Wang Y, Nayak S, Schneider JA, Ueberheide B, et al. Identification of PIM1 substrates reveals a role for NDRG1 phosphorylation in prostate cancer cellular migration and invasion. *Commun Biol*. 2021; 4: 36.
34. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. *Nature*. 2000; 407: 395-401.
35. Cohen P. Protein kinases--the major drug targets of the twenty-first century? *Nat Rev Drug Discov*. 2002; 1: 309-15.
36. Huse M, Kuriyan J. The conformational plasticity of protein kinases. *Cell*. 2002; 109: 275-82.
37. Park KC, Menezes SV, Kalinowski DS, Sahni S, Jansson PJ, Kovacevic Z, et al. Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. *Biochim Biophys Acta Mol Basis Dis*. 2018; 1864: 2644-63.
38. Wang Y, Wang Y, Wu C, Ji Y, Hou P, Wu X, et al. circEPB41L2 blocks the progression and metastasis in non-small cell lung cancer by promoting TRIP12-triggered PTBP1 ubiquitylation. *Cell Death Discov*. 2024; 10: 72.
39. Xuan L, Xu Z, Luo J, Wang Y, Yan Y, Qu C, et al. Lactate exacerbates lung damage induced by nanomicroplastic through the gut microbiota-HIF1a/PTBP1 pathway. *Exp Mol Med*. 2023; 55: 2596-607.
40. Ju Z, Lei M, Xuan L, Luo J, Zhou M, Wang Y, et al. P53-response circRNA_0006420 aggravates lung cancer radiotherapy resistance by promoting formation of HUR/PTBP1 complex. *J Adv Res*. 2023; S2090-1232(23)00203-5.
41. Hensel JA, Nicholas SE, Kimble AL, Nagpal AS, Omar OMF, Tyburski JD, et al.

Splice factor polypyrimidine tract-binding protein 1 (Ptbp1) primes endothelial inflammation in atherogenic disturbed flow conditions. *Proc Natl Acad Sci U S A*. 2022; 119: e2122227119.

42. Moore KJ, Koplev S, Fisher EA, Tabas I, Björkegren JLM, Doran AC, et al. Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2). *J Am Coll Cardiol*. 2018; 72: 2181-97.

43. Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. *J Cell Biol*. 2015; 209: 13-22.

44. Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. *J Clin Invest*. 2015; 125: 4514-28.

45. Piera-Velazquez S, Jimenez SA. Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. *Physiol Rev*. 2019; 99: 1281-324.

46. Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019; 73: 190-209.

47. Wesseling M, Sakkers TR, de Jager SCA, Pasterkamp G, Goumans MJ. The morphological and molecular mechanisms of epithelial/endothelial-to-mesenchymal transition and its involvement in atherosclerosis. *Vascul Pharmacol*. 2018; 106: 1-8.

48. Casillas AL, Chauhan SS, Toth RK, Sainz AG, Clements AN, Jensen CC, et al. Direct phosphorylation and stabilization of HIF-1 α by PIM1 kinase drives angiogenesis in solid tumors. *Oncogene*. 2021; 40: 5142-52.

49. Ko R, Seo J, Park H, Lee N, Lee SY. Pim1 promotes IFN- β production by interacting with IRF3. *Exp Mol Med*. 2022; 54: 2092-103.

50. Wu X, Chen Y, Jiang M, Guo L. PIM1 inhibitor SMI-4a attenuated concanavalin A-induced acute hepatitis through suppressing inflammatory responses. *Transl Gastroenterol Hepatol*. 2024; 9: 14.

51. Zhang Z, Xie S, Qian J, Gao F, Jin W, Wang L, et al. Targeting macrophagic PIM-1 alleviates osteoarthritis by inhibiting NLRP3 inflammasome activation via suppressing mitochondrial ROS/Ci(-) efflux signaling pathway. *J Transl Med*. 2023; 21: 452.

52. Zhang G, Qin Q, Zhang C, Sun X, Kazama K, Yi B, et al. NDRG1 Signaling Is Essential for Endothelial Inflammation and Vascular Remodeling. *Circ Res*. 2023; 132: 306-19.

53. Li A, Zhu X, Wang C, Yang S, Qiao Y, Qiao R, et al. Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT

process in bladder cancer. *Sci Rep.* 2019; 9: 5166.

54. Wang X, Sun R, Che N, Zhang D, Li Y, Zhao N. Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT. *Dig Liver Dis.* 2024; 56(8):1382-1399.

55. Zheng P, Wu Y, Wang Y, Hu F. Disulfiram suppresses epithelial-mesenchymal transition (EMT), migration and invasion in cervical cancer through the HSP90A/NDRG1 pathway. *Cell Signal.* 2023; 109: 110771.

56. Chang KS, Chen ST, Sung HC, Hsu SY, Lin WY, Hou CP, et al. WNT1 Inducible Signaling Pathway Protein 1 Is a Stroma-Specific Secreting Protein Inducing a Fibroblast Contraction and Carcinoma Cell Growth in the Human Prostate. *Int J Mol Sci.* 2022; 23(19):11437.

57. Ai R, Sun Y, Guo Z, Wei W, Zhou L, Liu F, et al. NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway. *Cancer Biol Ther.* 2016; 17: 943-54.

Figure Legends




Figure 1. PIM1 Is Significantly Elevated in Human Unstable Carotid Atherosclerosis Plaques and Mouse Advanced Atherosclerosis Plaques

(A) Uniform manifold approximation and projection (UMAP) visualization of vascular cells.

(B) Dot plot overview of expression of key marker genes identified for the cell types.

(C) Volcano plot showing differential expression genes of endothelial cells in 0 weeks and 26 weeks.

(D) Volcano plot showing differential expression genes of HUVECs in normal status and EndMT status.

(E) Venn diagram showing 13 overlapping genes between genes differentially expressed in mouse atherosclerotic plaques and genes identified in HUVECs.

(F) The expression level of PIM1 in endothelial cells of atherosclerotic plaques at different time points.

(G) Representative Western blot images and quantification of PIM1 levels in arcus aortae and thoracic aorta from normal diet (ND) and high fat diet (HFD) mice.

(H) Representative immunohistochemical and immunofluorescence images of PIM1 in sections of carotid artery of *ApoE*^{-/-} mice fed a normal diet (ND) and high fat diet (HFD) mice (n = 5). Scale bar of immunohistochemical = 100 μ m, Scale bar of immunofluorescence = 50 μ m.

(I) The PIM1 expression levels analysis based on RNA-seq data from GSE43292.

(J) Representative H&E, Masson and immunohistochemical, immunofluorescence images of PIM1 on stable and unstable plaques sections from human carotid artery (n = 10). Scale bar of H&E, Masson and immunohistochemical = 100 μ m, Scale bar of immunofluorescence = 500 μ m.

Data are shown as mean \pm SD. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.




Figure 2. PIM1 is Upregulated in Endothelial cells under the Conditions of ox-LDL Stimulation.

(A-C) qRT-PCR showing the transcript levels of ZEB1, ZO-1, VE-Cadherin, N-Cadherin, CD31, α-SMA, Slug, Snail and TAGLN in HUVEC, MAEC and MPLEC treated with ox-LDL (100 µg/mL, 48 h).

(D) qRT-PCR showing the transcript levels of PIM1 in HUVEC, MAEC and MPLEC treated with ox-LDL (100 µg/mL, 48 h).

(E) qRT-PCR showing the transcript levels of PIM1 in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).

(F) Representative Western blot images and quantification of PIM1, PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC treated with ox-LDL (100 μ g/mL, 48 h).

(G) Representative Western blot images and quantification of PIM1, PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(H) Representative immunofluorescence images to detect PIM1 expression in 100 μ g/mL ox-LDL-stimulated HUVEC. Scale bar = 20 μ m.

(I) Representative immunofluorescence images to detect PIM1 expression in 100 μ g/mL ox-LDL-stimulated MAEC. Scale bar = 20 μ m.

qRT-PCR Graph is representative of fold change relative to vehicle-treated control cells normalized to 1 (dashed line).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure 3. PIM1 Silence Attenuates the Process of EndMT

(A) qRT-PCR analysis of PIM1, CD31, VE-Cadherin, α -SMA, Slug and Snail mRNA levels in HUVEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h).

(B) qRT-PCR analysis of PIM1, CD31, VE-Cadherin, α -SMA, Slug and Snail mRNA levels in MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(C) Representative Western blot images and quantification of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(D) Representative Western blot images and quantification of ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with ox-LDL (100 μ g/mL, 48 h).

(E) Statistical analysis of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 3C, n = 3, Normalized to β -actin).

(F) Statistical analysis of ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with ox-LDL (100 μ g/mL, 48 h). (Figure 3D, n = 3, Normalized to β -actin).

(G) Endothelial scratch wound healing assays and Transwell assay were performed, showing that PIM1 silenced attenuated migration of HUVEC induced by H₂O₂ (200 μ M) and TGF- β (50 ng/mL). Scale bar of wound healing assays = 200 μ m. Scale bar of Transwell assay = 100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure 4. PIM447 Attenuates Atherosclerotic Plaque progress in vivo.

(A) Schematic representation of high-fat diet and pharmacological intervention in C57 *ApoE*^{-/-} mice.

(B) Representative photographs of atherosclerotic plaques in the aortic arches and carotid artery in the 2 groups (n = 5).

(C) Representative oil red O staining images of the atherosclerotic lesions in the whole aorta in the 2 groups (n = 5).

(D) Representative H&E staining images (left), oil red O staining images (middle), Masson staining images (right) of the aortic root in the 2 groups (n = 5). Scale bar = 500 μ m.

(E) Representative H&E staining images (left), oil red O staining images (middle), Masson staining images (right) of the carotid artery bifurcation in the 2 groups (n = 5). Scale bar = 250 μ m.

(F) Representative immunofluorescence staining images of F4/80 expression in aortic root sections in the 2 groups (n = 5). Scale bar of aortic root = 250 μ m.

(G) Representative immunofluorescence staining images of F4/80 expression in carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar of carotid artery bifurcation = 100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure 5. Endothelial Cell-Specific PIM1 Knockdown Reduces EndMT and Attenuates Atherosclerotic Plaque progress.

(A) Representative photographs and plaques area quantification of atherosclerotic plaques in the aortic arches and carotid artery in the 2 groups (n = 10).

(B) Representative oil red O staining images and quantification of the atherosclerotic lesions in the whole aorta in the 2 groups (n = 10).

(C) Representative H&E staining images (top), oil red O staining images (middle), Masson staining images (bottom) and quantification of the atherosclerotic lesion area, oil red O positive percentage, collagen positive percentage in the aortic root in the 2 groups (n = 10). Scale bar=500 μ m.

(D) Representative H&E staining images (top), oil red O staining images (middle), Masson staining images (bottom) and quantification of the atherosclerotic lesion area, oil red O positive percentage, collagen positive percentage in the carotid artery bifurcation in the 2 groups (n = 10). Scale bar=100 μ m.

(E) Representative immunohistochemical staining images of PIM1 protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =500 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(F) Representative immunohistochemical staining images of VE-Cadherin protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =500 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(G) Representative immunohistochemical staining images of Slug protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =500 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(H) Representative immunohistochemical staining images of Snail protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =500 μ m. Scale bar of carotid artery bifurcation =100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure 6. PIM1 Promotes the EndMT of Endothelial cell through phosphorylation of NDRG1 at Ser-330

(A) The proteins of input, IgG and anti-PIM1 were purified and size fractionated on 10% SDS-PAGE. The gel was stained by coomassie brilliant blue staining.

- (B) Venn diagram showing 1 overlapping protein (NDRG1) between protein mass spectrometry and already reported PIM1 phosphorylated substrates.
- (C) Representative Western blot images and quantification of P-NDRG1(S330), NDRG1 protein levels in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).
- (D) Representative Western blot images and quantification of P-NDRG1(S330), NDRG1 protein levels in HUVEC and MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).
- (E) Molecular simulations and protein docking of PIM1 and NDRG1.
- (F) Schematic diagrams of 6*His-Tagged full-length (WT) NDRG1, and their various deletion mutants (180-294aa, and 326-394aa) (Top). HEK 293T cells were co-transfected with His-Tagged NDRG1 or its deletion mutants or vectors, and whole cell lysates were assessed by immunoprecipitation followed by immunoblotting with anti-His-Tag and anti-PIM1 (bottom).
- (G) Schematic diagrams of Myc-Tagged wildtype (WT) PIM1, and Myc-Tagged mutant (Mut) PIM1.
- (H) HEK 293T cells were co-transfected with Myc-Tagged wildtype (WT) PIM1, Myc-Tagged mutant (Mut) PIM1 and whole cell lysates were assessed by immunoprecipitation followed by immunoblotting with anti-Myc-Tag and anti-NDRG1.
- (I) Fluorescence colocalization and quantification between PIM1 (Green), NDRG1 (Red) and α-SMA in HUVEC. Scale bar = 10 µm.
- (J) Representative Western blot images and quantification of NDRG1 nuclear protein levels in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).
- (K) Representative Western blot images and quantification of NDRG1 Nuclear protein levels in HUVEC and MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).

(L) Fluorescence localization and quantification of NDRG1 (Green) in HUVEC and MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h).

Data are shown as mean ± SD. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.




Figure 7. NDRG1 is Required for PIM1-Induced EndMT

(A) Representative Western blot images and quantification of P-NDRG1(S330), NDRG1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h).

(B) qRT-PCR analysis of NDRG1, CD31, ZO-1, Slug, Snail and α -SMA mRNA levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(C) Endothelial scratch wound healing assays and Transwell assay were performed, showing that NDRG1 silenced attenuated migration of HUVEC induced by H₂O₂ (200 μ M) and TGF- β (50 ng/mL). Scale bar of wound healing assays = 400 μ m. Scale bar of Transwell assay = 100 μ m.

(D) Representative Western blot images and quantification of P-NDRG1(S330), NDRG1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated as indicated and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(E) qRT-PCR analysis of Snail, Slug, α -SMA, VE-Cadherin and ZO-1 mRNA levels in HUVEC pretreated as indicated and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(F) The docking prediction of NDRG1 with Max-40279.

(G) Representative Western blot images and quantification of P-NDRG1(S330), NDRG1, ZEB1, N-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h), and treated with Max-40279 (0.5 μ M or 1 μ M, 48 h).

(H) Endothelial scratch wound healing assays and Transwell assay were performed, showing that Max-40279 attenuated migration of HUVEC induced by H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). Scale bar of wound healing assays = 400 μ m. Scale bar of Transwell assay = 100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure 8. NDRG1 and PTBP1 collaborate to promote EndMT

(A) The Nuclear and cytoplasm proteins of input, IgG and anti-His-Tag were purified and size fractionated on 10% SDS-PAGE. The gel was stained by coomassie brilliant blue staining.

(B) The content of NDRG1 was analyzed by NDRG1 antibody.

(C) The Co-IP experiment detecting the interaction between NDRG1 and PTBP1 in nucleus from HUVEC treated with H₂O₂ (200 μM) and TGF-β (50 ng/mL, 48 h).

(D, E) Molecular simulations and protein docking of NDRG1 and PTBP1.

(F) Schematic diagrams of 6*His-Tagged full-length (WT) NDRG1, and their various deletion mutants (180-294aa, and 326-394aa) (Top). HEK 293T cells were co-transfected with His-Tagged NDRG1 or its deletion mutants or vectors, and whole cell lysates were assessed by immunoprecipitation followed by immunoblotting with anti-His-Tag and anti-PTBP1 (bottom).

(G) Fluorescence colocalization and quantification between NDRG1 (Green) and PTBP1 (Red) in HUVEC. Scale bar = 25 μ m.

(H) Immunopurification of PTBP1/RNA complexes or control experiments (IgG) from HUVEC cell extracts. Immunopurification was controlled by PTBP1 Western blot analysis as indicated in IgG and IP samples (left). qRT-PCR and agarose gel electrophoresis after reverse transcription and PCR detection the different mRNA level (right).

(I) qRT-PCR analysis of PTBP1 mRNA levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(J) Representative Western blot images and quantification of total PTBP1 protein levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(K) Representative Western blot images and quantification of nuclear PTBP1 protein levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Supplementary Information

PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis

Author name and affiliations:

Zhiwei Xue^{1, 2*}, Mengtao Han^{1, 2*}, Tao Sun^{1, 2*}, Yanzhao Wu^{1, 2}, Wenchen Xing^{1, 2}, Feiyu Mu^{1, 2}, Zhihan Zhang^{1, 2}, Junzhi Liu^{1, 2}, Xiangjun Liang^{1, 2}, Lu Ling^{1, 2}, Jian Wang^{1, 2, 5}, Jiwei Wang^{1, 2}, Xingang Li^{1, 2, 3, 4}, Bin Huang^{1, 2, 3, 4}, Donghai Wang^{1, 2, 3}

1. Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University.

2. Shandong Key Laboratory of Brain Health and Function Remodeling, Jinan 250012, China.

3. Department of Neurosurgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China

4. Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Jinan, China

5. Department of Biomedicine, University of Bergen, Jonas Lies Vei 91, 5009, Bergen, Norway.

* Zhiwei Xue, Mengtao Han and Tao Sun contributed equally to this work

#Corresponding Author:

Donghai Wang, Ph.D. and M.D. (drwangdonghai@sdu.edu.cn)

Bin Huang, Ph.D. (hb@sdu.edu.cn)

Xingang Li, Ph.D and M.D. (lixg@sdu.edu.cn)

This supplementary information contains:

- 44 Pages
- Supplementary Figures (16 Figures, S1 to S16)
- Supplementary Tables (9 Tables, S1 to S9)

Supplementary Figures




Figure S1. The expression level of PIM1 in different cells of atherosclerotic plaques at different time points.

(A) The expression level of PIM1 in SMC of atherosclerotic plaques at different time points.

(B) The expression level of PIM1 in T cell of atherosclerotic plaques at different time

points.

(C) The expression level of PIM1 in ICS(SEM) of atherosclerotic plaques at different time points.

(D) The expression level of PIM1 in Fibroblast of atherosclerotic plaques at different time points.

(E) The expression level of PIM1 in Macrophage of atherosclerotic plaques at different time points.




Figure S2. Statistical analysis of PIM1 expression level.

(A) Statistical analysis of PIM1 levels in arcus aortae and thoracic aorta from normal diet (ND) and high fat diet (HFD) mice (Figure 1G, CD group n = 8, HFD group n = 9, Normalized to β -actin).

(B) Statistical analysis of PIM1 IHC Score in endothelial cells of carotid artery of *ApoE*^{-/-} mice fed a normal diet (ND) and high fat diet (HFD) mice (n = 5).

(C) Statistical analysis of PIM1 IHC Score in endothelial cells of stable and unstable plaques sections from human carotid artery (n = 10).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S3. PIM1 is Upregulated in Endothelial cells under the Conditions of ox-LDL Stimulation.

(A) The PIM1 expression levels analysis based on RNA-seq data from GSE206927.

(B) qRT-PCR showing the transcript levels of CD31, VE-Cadherin, ZO-1, ZEB1, TAGLN, N-Cadherin, SLUG, Snail, α -SMA, and vimentin in HUVEC treated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h).

(C) qRT-PCR showing the transcript levels of CD31, VE-Cadherin, ZO-1, ZEB1, TAGLN, N-Cadherin, SLUG, Snail, α -SMA, and vimentin in MAEC treated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h).

(D-F) Statistical analysis of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC treated with ox-LDL (100 μ g/mL, 48 h). (Figure 2F, n = 3, Normalized to β -actin).

(G-I) Statistical analysis of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 2F, n = 3, Normalized to β -actin).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S4. PIM1 Silence Attenuates the Process of EndMT.

(A) qRT-PCR analysis of ZEB1, N-Cadherin and TAGLN mRNA levels in HUVEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(B) qRT-PCR analysis of ZEB1, N-Cadherin and TAGLN mRNA levels in MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(C) Representative Western blot images and quantification of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).

(D) Statistical analysis of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in MAEC pretreated with siNC or

siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h).
(Figure S4C, n = 3, Normalized to β -actin).




Figure S5. PIM447 Attenuates the Process of EndMT

(A) qRT-PCR analysis of SLUG, Snail, TAGLN, ZEB1, α-SMA, VE-Cadherin and ZO-1 mRNA levels in HUVEC stimulated with H₂O₂ (200 μM) and TGF-β (50 ng/mL, 48h) and treated with PIM447 (0, 5, 10 μM, 48 h).

(B) qRT-PCR analysis of SLUG, Snail, TAGLN, ZEB1, α-SMA, VE-Cadherin and ZO-1 mRNA levels in MAEC stimulated with H₂O₂ (200 μM) and TGF-β (50 ng/mL, 48 h) and treated with PIM447 (0, 5, 10 μM, 48 h).

(C) Representative Western blot images and quantification of ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α-SMA, Slug, Snail and TAGLN levels in HUVEC

and MAEC stimulated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h) and treated with PIM447 (0, 5, 10 µM, 48 h).

(D) Statistical analysis of ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α-SMA, Slug, Snail and TAGLN levels in HUVEC and MAEC stimulated with H₂O₂ (200 µM) and TGF-β (50 ng/mL, 48 h) and treated with PIM447 (0, 5, 10 µM, 48 h). (Figure S5C, n = 3, Normalized to β-actin).

Data are shown as mean ± SD. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.




Figure S6. PIM447 Attenuates the Process of EndMT.

(A) Endothelial scratch wound healing assays and Transwell assay were performed, showing that PIM1 silenced attenuated migration of MAEC induced by H₂O₂ (200 μM) and TGF-β (50 ng/mL). Scale bar of wound healing assays = 400 μm. Scale bar of Transwell assay = 100 μm.

(B) Endothelial scratch wound healing assays and Transwell assay were performed, showing that PIM447 attenuated migration of HUVEC induced by H₂O₂ (200 μM) and TGF-β (50 ng/mL). Scale bar of wound healing assays = 200 μm. Scale bar of Transwell assay = 100 μm.

(C) Endothelial scratch wound healing assays and Transwell assay were performed, showing that PIM447 attenuated migration of MAEC induced by H₂O₂ (200 μM) and

TGF- β (50 ng/mL). Scale bar of wound healing assays = 200 μ m. Scale bar of Transwell assay = 100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S7. PIM447 inhibits the endothelial cell inflammation in vivo.

(A) Representative immunofluorescence staining images of ICAM1 expression in aortic root and carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(B) Representative immunofluorescence staining images of VCAM1 expression in aortic root and carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.




Figure S8. PIM447 Attenuates the process of EndMT in vivo.

(A) Representative immunofluorescence staining images of SLUG protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(B) Representative immunofluorescence staining images of Snail protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(C) Representative immunofluorescence staining images of TAGLN protein levels in carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar =100 μ m.

(D) Representative immunofluorescence staining images of α -SMA protein levels in carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar =100 μ m.

(E) Representative immunofluorescence staining images of VE-Cadherin protein levels in carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar =100 μ m.

(F) Representative immunofluorescence staining images of N-Cadherin protein levels in carotid artery bifurcation sections in the 2 groups (n = 5). Scale bar =100 μ m.




Figure S9. PIM1 Silence Attenuates the Process of EndMT

(A) Time axis of mouse model construction for atherosclerosis.

(B) Schematic diagram of the MPLEC extraction process.

(C) Representative Western blot images and quantification of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α-SMA, Slug, Snail and TAGLN levels in MPLEC from 2 different group as indicated stimulated with H₂O₂ (200 μM) and TGF-β (50 ng/mL, 48 h).

(D) Statistical analysis of PIM1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in MPLEC from 2 different group as indicated stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure S9C, n = 3, Normalized to β -actin).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S10. Endothelial Cell-Specific PIM1 Knockdown Reduces EndMT and Attenuates Atherosclerotic Plaque progress.

(A) Statistical analysis of the fibrous cap area in aortic root sections in the 2 groups (n = 10).

(B) Statistical analysis of the fibrous cap area in carotid artery bifurcation sections in the 2 groups (n = 10).

(C) Representative immunofluorescence staining images of F4/80 expression in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(D) Representative immunofluorescence staining images of ICAM1 expression in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(E) Representative immunofluorescence staining images of VCAM1 expression in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S11. Endothelial Cell–Specific PIM1 Deletion Reduces EndMT.

(A) Representative immunofluorescence staining images of PIM1 protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(B) Representative immunofluorescence staining images of Snail protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(C) Representative immunofluorescence staining images of α -SMA protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.

(D) Representative immunofluorescence staining images of TAGLN protein levels in aortic root and carotid artery bifurcation sections in the 2 groups (n = 10). Scale bar of aortic root =250 μ m. Scale bar of carotid artery bifurcation =100 μ m.




Figure S12. NDRG1 is Required for PIM1-Induced EndMT

(A) Statistical analysis of P-NDRG1 and NDRG1 levels in HUVEC, MAEC and MPLEC treated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 6C, n = 3, Normalized to β -actin).

(B) Statistical analysis of P-NDRG1 and NDRG1 levels in HUVEC and MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 6D, n = 3, Normalized to β -actin).

(C) The Co-IP experiment detecting the interaction between PIM1 and NDRG1 in HUVEC treated with H_2O_2 (200 μ M) and TGF- β (50 ng/mL, 48 h).

(D) Red lines represent the global interaction of PIM1 with NDRG1 in the SPR assay.

(E) Fluorescence colocalization and quantification between PIM1 (Green) and NDRG1 (Red) in MAEC. Scale bar = 10 μ m.

(F) Statistical analysis of NDRG1 nuclear protein levels in HUVEC, MAEC and MPLEC treated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 6K, n = 3, Normalized to H3).

(G) Statistical analysis of NDRG1 nuclear protein levels in HUVEC and MAEC pretreated with siNC or siPIM1-1, siPIM1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 6L, n = 3, Normalized to H3).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S13. NDRG1 is Required for PIM1-Induced EndMT

(A) Statistical analysis of P-NDRG1, NDRG1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α-SMA, Slug, Snail and TAGLN levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μM) and TGF-β (50 ng/mL, 48 h). (Figure 7A, n = 3, Normalized to β-actin).

(B) Statistical analysis of P-NDRG1, NDRG1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated as indicated and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 7D, n = 3, Normalized to β -actin).

(C) Representative Western blot images and statistical quantification of P-NDRG1(S330), NDRG1, ZO-1, ZEB1, CD31, N-Cadherin, VE-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC pretreated as indicated and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure S13C, n = 3, Normalized to β -actin).

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S14. NDRG1 is Required for PIM1-Induced EndMT

(A) Red lines represent the global interaction of PIM1 with NDRG1 in the SPR assay.

(B-D) Statistical analysis of P-NDRG1, NDRG1, ZEB1, N-Cadherin, Vimentin, α -SMA, Slug, Snail and TAGLN levels in HUVEC, MAEC and MPLEC stimulated with H_2O_2 (200 μ M) and TGF- β (50n g/mL, 48 h), and treated with Max-40279 (0.5 μ M or 1 μ M, 48 h). (Figure 7G, n = 3, Normalized to β -actin).

(E) Endothelial scratch wound healing assays and Transwell assay were performed, showing that Max-40279 attenuated migration of MAEC induced by H_2O_2 (200 μ M) and TGF- β (50 ng/mL). Scale bar of wound healing assays = 200 μ m. Scale bar of Transwell assay = 100 μ m.

(F) Endothelial scratch wound healing assays and Transwell assay were performed, showing that Max40279 attenuated migration of MPLEC induced by H_2O_2 (200 μM) and TGF- β (50 ng/mL). Scale bar of wound healing assays = 200 μm . Scale bar of Transwell assay = 100 μm .

Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S15. NDRG1 and PTBP1 collaborate to promote EndMT

(A) Red lines represent the global interaction of NDRG1 with PTBP1 in the SPR assay.

(B) Fluorescence colocalization and quantification between NDRG1 (Green) and PTBP1 (Red) in MAEC. Scale bar = 25 μ m.




Figure S16. NDRG1 and PTBP1 collaborate to promote EndMT

(A) Immunoprecipitation of PTBP1/RNA complexes or control experiments (IgG) from HUVEC cell extracts. qRT-PCR and agarose gel electrophoresis after reverse transcription and PCR detection the different mRNA level.

(B) The docking prediction of PTBP1 with Vimentin.

(C) The docking prediction of PTBP1 with SLUG.

- (D) The docking prediction of PTBP1 with α -SMA.
- (E) The docking prediction of PTBP1 with Snail.
- (F) The docking prediction of PTBP1 with ZEB1.
- (G) The docking prediction of PTBP1 with TAGLN.
- (H) The docking prediction of PTBP1 with N-Cadherin.
- (I) Statistical analysis of PTBP1 nuclear and total proteins levels in HUVEC pretreated with shNC or shNDRG1-1, shNDRG1-2 and stimulated with H₂O₂ (200 μ M) and TGF- β (50 ng/mL, 48 h). (Figure 7J, K, n = 3, Normalized to β -actin and H3).
Data are shown as mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Supplementary Tables

Table S1. Clinical data of Carotid atherosclerotic plaque patients involved in our study

Patient ID	Age at Surgery	Gender	Symptom	Plaque Status
21079150	65	Male	None	Stable
22029662	68	Female	None	Stable
22066510	57	Male	None	Stable
22074809	66	Male	None	Stable
22086769	66	Male	None	Stable
22099771	65	Male	None	Stable
22106659	60	Male	None	Stable
22155895	66	Male	None	Stable
22032335	74	Male	None	Stable
22087705	74	Female	None	Stable
22032484	74	Male	Yes	Unstable
22040294	64	Male	Yes	Unstable
22046392	67	Male	Yes	Unstable
22046504	58	Female	Yes	Unstable
22060724	74	Male	Yes	Unstable
22074849	71	Male	Yes	Unstable
22130905	69	Male	Yes	Unstable

22140380	72	Female	Yes	Unstable
22175444	74	Male	Yes	Unstable
23012420	68	Female	Yes	Unstable

Table S2. siRNA sequences used in this study

siRNA	Sequence (5'-3')
Homo-siPIM1-1	CAAGAUCUCUUCGACUUCATT
Homo-siPIM1-2	GGAUCCUGCUGUAUGAUAUTT
Mus-siPIM1-1	ACACAGUCUACACGGACUUTT
Mus-siPIM1-2	CCGAUAGUUUCGUGCUGAUTT

Table S3. shRNA sequences used in this study

shRNA	Sequence (5'-3')
Homo-Lenti-shNDRG1-1	GCCTACATCCTAACTCGATTT
Homo-Lenti-shNDRG1-2	CCTGGAGTCCTTCAACAGTTT
Mus-AAV9-shPim1	CCGAUAGUUUCGUGCUGAUTT

Table S4. Plasmids used in this study

Plasmids	Sequence (5'-3')
Homo-PIM1	Homo-Pim1-N-MYC in PCDNA3.1
Homo-NDRG1	Homo-NDRG1(NM_001135242.2)-C-HIS in PCDNA3.1
Homo-NDRG1(S330A)	Homo-NDRG1(S330A)-C-HIS in PCDNA3.1
Homo-NDRG1(S330D)	Homo-NDRG1(S330D)-C-HIS in PCDNA3.1
Homo-NDRG1(del:180-294aa)	Homo-NDRG1(del:180-294aa)-C-HIS in PCDNA3.1
Homo-NDRG1(del:326-350aa)	Homo-NDRG1(del:326-350aa)-C-HIS in PCDNA3.1

Table S5. qRT-PCR primers used in this study

Gene	Forward (5'-3')	Reverse (5'-3')
Homo-PIM1	AAAATCAACTCGCTTGCCCAC	CTGAGTAGACCGAGCCGAAG
Homo-ZEB1	AATTCACAGTGGAGAGAAGCCA	GGTCGCCCATTACAGGTAT
Homo-ZO-1	TCACGCAGTTACGAGCAAGT	TGAAGGTATCAGCGGAGGGA
Homo-VE-	GCATCGGTTGTTCAATGCGT	CGCTTCCACCACGATCTCAT
Cadherin		
Homo-N-	TCCTGCTTATCCTTGTGCTGA	AAAAGTTGTTTGGCCTGGCG
Cadherin		
Homo-CD31	GCTGACCCTTCTGCTCTGTT	ATCTGGTGCTGAGGCTTGAC
Homo- α -	ATGCCTCTGGACGCACAACT	CCCGGACAATCTCACGCTCA
SMA		
Homo-Slug	GAGCATACAGCCCCATCACT	CTCACTCGCCCCAAAGATGA
Homo-Snail	GACCCCAATCGGAAGCCTAA	AGGGCTGCTGGAAGGTAAAC
Homo-	TGAAGGCGGCTGAGGACTAT	ATCTCCACGGTAGTGCCCAT
TAGLN		
Homo- β -	GAAGAGCTACGAGCTGCCTGA	CAGACAGCACTGTGTTGGCG
actin		
Homo-	CGACCTGGAGATTGAGCGAC	CCGCCATCTTGAGGAGAGTG
NDRG1		
Homo-	TACAAAGCGGGGATCTGACG	TCGGCTGTCACCTTTGAACT

PTBP1

Mus-PIM1 TGGATTCGCTACCATCGCTAC TCTTCATCGTGCTCAAACGGA

Mus-ZEB1 GGGACCTCAATGCACTTCCA GTGGCTGACTGGGAGACAAA

Mus-ZO-1 GATTTACCCGTCAGCCCTTCT TGGGCCTAAGTATCCCGTCT

Mus-VE- AAGACATCCGAGTGGGCAAG CTGTACTCGCCCTGCATGAT

Cadherin

Mus-N- GGCAATCCCACCTTATGGCCT TCCGTGACAGTTAGGTTGGC

Cadherin

Mus-CD31 GCATCGGCAAAGTGGTCAAG GGGTGCAGTTCCATTTTCGG

Mus- α -SMA TTCGTGACTACTGCCGAGC GTCAGGCAGTTCGTAGCTCT

Mus-Slug AGAAGCCCAACTACAGCGAA ATAGGGCTGTATGCTCCCGA

Mus-Snail ACCCTCATCTGGGACTCTCTC CAGCGAGGTCAGCTCTACG

Mus-TAGLN TGGCTGTGACCAAAAACGATG TGCTCCTGGGCTTTCTTCATA

Mus- β -actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT

Mus-NDRG1 ACAAGACCTGCTACAACCCC AGCCCAAACCTGGTGAAGGAC

Table S6. Antibodies used in this study

Antibodies	Manufacturer	Cat No.	Applications
β -actin	Proteintech	66009-1-Ig	WB
PIM1	Abcam	ab300453	WB, IP
PIM1	Santa	sc-374116	IF, IHC
CD31	Servicebio	GB11063-2-100	WB, IF
CD31	Servicebio	GB12063-100	IF
CD31	Servicebio	GB12064-100	IF
ZO-1	Thermo Fisher	33-9100	WB
ZEB1	CST	70512S	WB
N-Cadherin	Proteintech	22018-1-AP	WB
N-Cadherin	Proteintech	66219-1-Ig	IF
VE-Cadherin	CST	2500S	WB
VE-Cadherin	Proteintech	66804-1-Ig	IF, IHC
Vimentin	Proteintech	10366-1-AP	WB
α -SMA	Proteintech	67735-1-Ig	WB
α -SMA	Abcam	ab7817	IF
Slug	CST	9585S	WB
Slug	Santa	sc-166476	IF, IHC
Snail	CST	3879S	WB
Snail	Santa	sc-271977	IF, IHC

TAGLN	Proteintech	10493-1-AP	WB
TAGLN	Proteintech	60213-1-Ig	IF
NDRG1	Abcam	ab124689	WB, IF, IP
NDRG1(phospho S330)	Abcam	ab124713	WB
Histone H3	CST	9715S	WB
PTBP1	Proteintech	67462-1-Ig	WB
PTBP1	Proteintech	12582-1-AP	WB, IF, IP, RIP
Myc-Tag	CST	2276S	IP
6*His-Tag	Proteintech	10001-0-AP	WB
6*His-Tag	Proteintech	66005-1-Ig	IP

Table S7. The identified proteins interacted with PIM1 by LC–MS/MS analysis

MS4A10	ACTB	EEF1A2	IMPDH2	ABCA5
NDRG1	MYH9	MYH10	S100A8	IGKV4-1
KRT1	KRT2	KRT5	KRT16	TFAM
SNPH	STAG2	VIM	IGKC	TMPO
KRT10	NUDCD2	KRT14	KRT17	KRT6B
KRT9	PIM1	MYL6	H1-3	ACTA1
ALB	IGKV2-29	TUBA3D	HRNR	TUBB
CACNB2	DCD			

Table S8 The top five small molecule drugs with NDRG1 have the lowest binding energies

No.	Name	Cas ID	Binding energies
	N-[2-(Carbamimidamidooxy)ethyl]-	-	
4159	2-{6-Cyano-3-[(2,2-Difluoro-2-Pyridin-2-Ylethyl)amino]-2-Fluorophenyl}acetamide		-5
	2-(6-Chloro-3-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluoro-6-pyridinyl)methyl]acetamide	312904-60-2	-4.4
4059			
7482	MAX-40279	2070931-57-4	-4.4
6905	Naftazone	15687-37-3	-4.2
7802	Stenoparib	1140964-99-3	-4.2

Table S9. The identified proteins interacted with NDRG1 in nuclear proteins by LC–MS/MS analysis

Gene ID	Protein ID	Peptides	Score	Abundances
MYH8	P13535	2	4.08	78104912.0
ADAMTSL4	Q6UY14	1	2.33	40128336.0
TBKBP1	A7MCY6	1	3.24	39052456.0
TUBA3D	P0DPH8	5	18.92	4632357.625
MBP	P02686	2	5.55	3938560.84375
GRIA1	P42261	1	0.0	3080987.0
PLP1	P60201	3	6.89	2602124.1875
TUBB	P07437	7	13.04	2114089.625
NDRG1	Q92597	3	12.88	1801817.34375
RPL27A	P46776	1	2.3	1240122.625
PARP1	P09874	3	7.02	1188897.90625
ATP1A2	P50993	5	10.52	959354.015625
IGLL5	B9A064	1	2.29	944982.0
HNRNPK	P61978	2	4.65	867004.40625
H2AZ2	Q71UI9	1	7.22	831455.9375
LMNB1	P20700	3	7.59	775806.375
HNRNPH1	P31943	4	9.72	755502.46875
ATP5F1A	P25705	3	6.67	686215.921875
NPM1	P06748	1	2.31	634930.625
RAN	P62826	1	2.03	623162.9375
YWHAZ	P63104	2	3.93	596841.3125
RPS13	P62277	1	2.13	483881.71875
RBMX	P38159	1	1.95	444043.5625
ATP5F1B	P06576	2	7.09	388387.921875
RPS8	P62241	1	2.14	374163.3125
RPS23	P62266	1	1.99	373401.625
SRSF7	Q16629	1	0.0	359095.53125
DHX9	Q08211	1	5.38	349699.625
NCL	P19338	1	1.92	345739.78125
SAFB	Q15424	1	2.12	341473.28125
HSPA7	P48741	1	2.15	336358.9375
PTBP1	P26599	1	1.98	318917.15625

Gene ID	Protein ID	Peptides	Score	Abundances
RPL29	P47914	1	1.91	311830.625
HSP90AA1	P07900	1	1.97	305896.53125
CKB	P12277	1	2.1	293870.84375
LBR	Q14739	1	0.0	285852.0625
ILF2	Q12905	1	0.0	285054.875
ALDOA	P04075	1	2.24	257677.609375
RPL7	P18124	1	2.19	221118.421875
TMPO	P42167	1	1.99	210581.328125
ILF3	Q12906	1	2.06	201099.25
RPL8	P62917	1	2.31	199844.5625
DPYSL2	Q16555	1	2.95	198080.390625
SRSF8	Q9BRL6	1	2.24	196025.046875
LMNA	P02545	1	2.06	192719.828125
MDH2	P40926	1	2.04	192424.140625
H1-10	Q92522	1	1.92	148243.59375
RCC1	P18754	1	2.35	136217.640625
RNASE4	P34096	1	2.54	0
PKM	P14618	1	2.48	0
H2AC1	Q96QV6	1	3.63	0
RPL13	P26373	1	2.53	0
QRICH1	Q2TAL8	1	0.0	0